Given the significant clinical responses observed with anti-PD-L1 therapies in CPS > 1 tumors and HER-2 therapies in HER-2 positive disease when individually added to standard chemotherapy regimens in advanced or metastatic G/GEJ adenocarcinoma,36,37 their use in combination has been investigated for HER2-positive advanced or metastatic G/GEJ adenocarcinoma in KEYNOTE-811. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.